In vivo, LJ001 demonstrates no toxicity in mice following oral gavage or intraperitoneal administration daily for 7 days at doses of 20 and 50 mg/kg^[2].

With a CC50 value of 146.4 μM for ST cells, LJ001 exhibits minimal cytotoxicity over 24 hours, even at concentrations as high as 200 μM^[1].

At a concentration of 12.5 µM, LJ001 suppresses both TGEV and PDCoV infections and their gene mRNA expression in ST cells across various time points^[1].

Additionally, LJ001's antiviral efficacy extends to inhibiting the entry and spread of multiple enveloped viruses, including HIV, HCV, influenza, Ebola, arenaviruses, and poxviruses^[1].